The invention relates to a compound chosen from the compounds of formulae (I) and (II), the leucoforms thereof, the optical and geometrical isomers thereof and the tautomers thereof, and also the addition salts thereof with an acid or a base, and the solvates thereof. The invention also relates to the use of these particular compounds for dyeing keratin fibres.

##STR00001##

The present subject matter provides compounds, compositions, and methods for identifying, monitoring, treating, and removing diseased tissue. Compounds, compositions, and methods for identifying, monitoring, and detecting circulating fluids such as blood are also provided.

The present subject matter provides compounds, compositions, and methods for identifying, monitoring, treating, and removing diseased tissue. Compounds, compositions, and methods for identifying, monitoring, and detecting circulating fluids such as blood are also provided.

A composite pigment includes first and second cholesteric liquid crystal pigments. The first cholesteric liquid crystal pigment has a center wavelength of a selective reflection band within a wavelength range of 400 nm or more and 800 nm or less and a selective reflection bandwidth of 150 nm or less. The second cholesteric liquid crystal pigment has a selective reflection bandwidth of 200 nm or more within a wavelength range of 400 nm or more and 800 nm or less. The selective reflection band of the first cholesteric liquid crystal pigment and a selective reflection band of the second cholesteric liquid crystal pigment at least partially overlap with each other. A containing amount of the first cholesteric liquid crystal pigment relative to a total amount of the first and second cholesteric liquid crystal pigments is more than 30% by weight and 80% by weight or less.

A composite pigment includes first and second cholesteric liquid crystal pigments. The first cholesteric liquid crystal pigment has a center wavelength of a selective reflection band within a wavelength range of 400 nm or more and 800 nm or less and a selective reflection bandwidth of 150 nm or less. The second cholesteric liquid crystal pigment has a selective reflection bandwidth of 200 nm or more within a wavelength range of 400 nm or more and 800 nm or less. The selective reflection band of the first cholesteric liquid crystal pigment and a selective reflection band of the second cholesteric liquid crystal pigment at least partially overlap with each other. A containing amount of the first cholesteric liquid crystal pigment relative to a total amount of the first and second cholesteric liquid crystal pigments is more than 0% by weight and 30% by weight or less.

Problem to Be Solved: to provide a chromophore having a far superior nonlinear optical activity to conventional chromophores and to provide a nonlinear optical element comprising said chromophore. Solution: a chromophore comprising a donor structure D, a -conjugated bridge structure B, and an acceptor structure A, the donor structure D comprising an aryl group substituted with a substituted oxy group; and a nonlinear optical element comprising said chromophore.

The present subject matter provides compounds, compositions, and methods for identifying, monitoring, treating, and removing diseased tissue. Compounds, compositions, and methods for identifying, monitoring, and detecting circulating fluids such as blood are also provided.

The present invention relates to a complex comprising at least one dendrimer and at least one lanthanide, wherein the dendrimer comprises a unit of formula (I) below:

##STR00001##

in which: C.sub.1 is a valence group 4 of formula >NCH.sub.2CH.sub.2N<; A.sub.1, A.sub.2 and A.sub.3 are groups of formula (CH.sub.2).sub.2C(O)NH(CH.sub.2).sub.2; the unit of formula (I) being connected covalently to at least one antenna which absorbs at a wavelength ranging from 500 nm to 900 nm.

The present subject matter provides compounds, compositions, and methods for identifying, monitoring, treating, and removing diseased tissue. Compounds, compositions, and methods for identifying, monitoring, and detecting circulating fluids such as blood are also provided.

The present subject matter provides compounds, compositions, and methods for identifying, monitoring, treating, and removing diseased tissue. Compounds, compositions, and methods for identifying, monitoring, and detecting circulating fluids such as blood are also provided.